Chitin and chitinases in SARS-CoV-2 infection
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 1R21AI163640-01A1
Grant search
Key facts
Disease
COVID-19, OtherStart & end year
20232025Known Financial Commitments (USD)
$194,584Funder
National Institutes of Health (NIH)Principal Investigator
Steven Van DykenResearch Location
United States of AmericaLead Research Institution
WASHINGTON UNIVERSITYResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
ABSTRACT Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and resultant coronavirus disease 2019 (COVID-19) has caused a global health crisis, surpassing 100 million infections in the United States. SARS- CoV-2 infections range from asymptomatic to respiratory failure and death, and can result in an array of long- term effects collectively referred to as post-acute sequelae of SARS-CoV-2 infection (PASC). The pathobiological mechanisms and environmental factors underlying the intensity and duration of these effects remain unclear, but a range of chronic lung impairments that resemble complications associated with age-related pulmonary fibrosis have been documented in severe COVID-19, suggesting that environmental drivers implicated in pulmonary fibrosis may also influence the course of SARS-CoV-2 infection and PASC. We have identified the environmental constituent chitin as a candidate environmental driver of persistent SARS-CoV-2- induced disease, consistent with its previously described role in pulmonary fibrosis. Our preliminary studies show that chitin spontaneously accumulates in the lungs of SARS-CoV-2-infected mice, and is accompanied by alterations in the expression patterns of the major lung chitinase, AMCase, suggesting that chitin-chitinase interactions may contribute to SARS-CoV-2 pathogenesis. In comparison with wild-type (WT) controls, mice that genetically lack AMCase exhibit exacerbated lung pathology after infection with SARS-CoV-2, implicating chitin and chitinases in the pathologic sequelae that occur during the recovery phase. Thus, we hypothesize that environmental chitin can drive COVID-19 severity, epithelial dysregulation, and disease persistence, and that epithelial chitinases attenuate this process by degrading chitin. In this project, we leverage recently developed mouse models of SARS-CoV-2 infection and chitin exposure to delineate a host-environmental interaction that may contribute to persistent lung impairments following SARS-CoV-2 infection. We will test our hypothesis by addressing two Aims: (1) determine the influence of environmental chitin on the severity and persistence of lung pathology after SARS-CoV-2 infection, and (2) define the role of mammalian chitinases in SARS-CoV-2 infection and persistent lung disease. Understanding how environmental chitin influences long-lasting pathologic responses after SARS-CoV-2 infection may lead to the identification of new biomarkers and therapeutic targets associated with differential disease outcomes in COVID-19 and PASC.